Use of the Butantan’s anti-CD3 in renal transplantation

Purposes: The monoclonal anti-CD3 antibody has been used as induction and to treat acute rejection episodes in organ transplantation. This retrospective study reports a trial in three Brazilian transplantation centers, which have used a national anti-CD3 preparation developed by the Butantan Institu...

Descripción completa

Detalles Bibliográficos
Autores: Lemos, Francine, Marques, Flavio, Castro, Maria Cristina Ribeiro, Ianhez, Luiz Estevam, Moro, Ana Maria, Rodrigues, Maria Teresa Alves, Garbuio, Angélica, Raw, Isaias, Monteiro, Sandra Maria, Coelho, Verônica, Kalil, Jorge, Pestana, Jose Osmar Medina, Garcia, Valter Duro, Neumann, Jorge
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2006
País:Brasil
Institución:Associação Brasileira de Transplante de Órgãos (ABTO)
Repositorio:Brazilian Journal of Transplantation
Idioma:portugués
OAI Identifier:oai:ojs3.emnuvens.com.br:article/367
Acceso en línea:https://bjt.emnuvens.com.br/revista/article/view/367
Access Level:acceso abierto
Palabra clave:Muromonab-CD3
Transplante de Rim
Imunossupressão
Rejeição de Enxerto
Muromanab-CD3
Kidney Transplantation
Imunosupression
Graft Rejection
Descripción
Sumario:Purposes: The monoclonal anti-CD3 antibody has been used as induction and to treat acute rejection episodes in organ transplantation. This retrospective study reports a trial in three Brazilian transplantation centers, which have used a national anti-CD3 preparation developed by the Butantan Institute (São Paulo, Brazil), in renal transplant patients. Methods: Twenty-five patients have used anti-CD3 as induction therapy (n=9) or to treat acute rejection (n=16). Results: Most patients (89%) using anti-CD3 for induction were sensitized, and 33% of cases experienced acute rejection. The therapeutic use was indicated to treat cortical-resistant rejection or episodes of major histological severity, and it promoted the clinical reversion in 69% of cases. In the majority of patients, the use of the Butantan CD3 reduced the amount of CD3+ cells to lower than 30cells/mm3 at the second treatment day. Most frequent adverse event was fever, and bacterial and viral infections in 13 and 10 patients, respectively. Up to the middle of the 8 follow-up years, no tumor case was reported. Conclusion: Concluding, the use of Butantan anti-CD3 has shown effectiveness in preventing and to treat acute rejection in renal transplantation.

Similares en LA Referencia